An Open-Label, Multicenter, Phase III Study to Assess the Impact of Transient Androgenic Deprivation With Enantone LP 11.25 Mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer.
Phase of Trial: Phase III
Latest Information Update: 17 Dec 2016
At a glance
- Drugs Leuprorelin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Takeda
- 10 Jun 2017 Biomarkers information updated
- 06 Dec 2016 Status changed from active, no longer recruiting to completed.
- 20 Apr 2016 Planned End Date changed from 1 Apr 2016 to 1 Jul 2016.